| Identification | Back Directory | [Name]
Benzonitrile, 5-(2,3-dihydro-3-oxo-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-(1-methylethoxy)- | [CAS]
2642137-96-8 | [Synonyms]
Xanthine oxidase-IN-4
Benzonitrile, 5-(2,3-dihydro-3-oxo-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-(1-methylethoxy)- | [Molecular Formula]
C15H13N5O2 | [MOL File]
2642137-96-8.mol | [Molecular Weight]
295.3 |
| Hazard Information | Back Directory | [Uses]
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research[1]. | [in vivo]
Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid[1]. | Animal Model: | Sprague-Dawley rats (Six weeks, male, 180-200g, six groups)[1] | | Dosage: | 10 mg/kg | | Administration: | Intragastrically, once | | Result: | Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%. |
| [References]
[1] Zhao J, et al. Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors. Eur J Med Chem. 2022;229:114086. DOI:10.1016/j.ejmech.2021.114086 |
|
|